2024/09/30 更新

写真a

マツオ セイコ
松尾 聖子
MATSUO Seiko
所属
医学部附属病院 産科婦人科 病院助教
職名
病院助教

学位 1

  1. 博士(医学) ( 2024年3月   名古屋大学 ) 

 

論文 5

  1. TJP1 suppresses trophoblast cell invasion by expressing E2F8 in the human placenta

    Miki, R; Matsuo, S; Ushida, T; Tano, S; Imai, K; Nawa, A; Kajiyama, H; Kotani, T

    MOLECULAR AND CELLULAR ENDOCRINOLOGY   591 巻   頁: 112277   2024年9月

     詳細を見る

    記述言語:英語   出版者・発行元:Molecular and Cellular Endocrinology  

    Adequate extravillous trophoblast (EVT) invasion into the maternal decidua is important for human placental development. We identified that E2F transcription factor 8 (E2F8) suppresses EVT invasion, and that tight junction protein-1 (TJP1) is a potential downstream target gene of E2F8. We investigated the role of TJP1 in the human placenta and regulation of TJP1 expression by E2F8. TJP1 expression decreased in E2F8 knockdown HTR-8/SVneo cells. TJP1 and E2F8 were co-expressed in villi in the first-trimester placenta and in EVTs and villi in the third-trimester placenta. TJP1 was significantly increased in the pre-eclamptic compared with control placenta. TJP1 knockdown increased the invasion of HTR-8/SVneo cells, while TJP1 overexpression inhibited cell invasion. Halo-E2F8 overexpression significantly increased TJP1 expression and TJP1 transcription compared with control placenta. Our findings suggest that E2F8 promotes TJP1 transcription, and that TJP1 expression by E2F8 inhibits EVT invasion. TJP1 and E2F8 may be related to pre-eclampsia pathogenesis.

    DOI: 10.1016/j.mce.2024.112277

    Web of Science

    Scopus

    PubMed

  2. Identifying the high-benefit population for weight management-based cardiovascular disease prevention in Japan

    Tano, S; Kotani, T; Matsuo, S; Ushida, T; Imai, K; Kajiyama, H

    PREVENTIVE MEDICINE REPORTS   43 巻   頁: 102782   2024年7月

     詳細を見る

    記述言語:英語   出版者・発行元:Preventive Medicine Reports  

    Background: Cardiovascular-disease (CVD) is the leading cause of death, and the association between obesity and CVD is particularly significant among women. Given the evidence highlighting the significance of weight-gain velosity, we aimed to elucidate its influence on cardio-ankle vascular index (CAVI), a reliable surrogate marker of CVD, and identify the high-benefit population where this influence is most pronounced. Methods: This multicenter retrospective study used electronic data from annual health checkups for workers in Japan. Individuals who voluntarily measured CAVI in 2019 were included, and weight-gain velosity was defined as the mean BMI gain from 2015 to 2019. Our primary outcome was the relationship between weight-gain velosity and CAVI. Results: Among 459 individuals, 53 had CAVI ≥ 9. Random forest analysis revealed that age was the most important factor, followed by lipid metabolism, weight-gain velosity, and glucose metabolism, with sex being the least important. Non-linear regression analysis of the effect of age on CAVI ≥ 9 showed the effect was pronounced after age 60, and the trend was greater in women. Among individuals aged 60 or younger, the aOR of weight-gain velosity for CAVI ≥ 9 was significantly positive (aOR 11.95, 95 %CI 1.13–126.27), while it was not significant for those older than 60. The relationship between weight-gain velosity and CAVI provides a new perspective on CVD risk factors. The effects of age, especially after 60, and weight-gain velosity in early- to middle-adulthood on arterial stiffness are emphasized. Conclusions: These findings underscore the importance of weight management under age 60, especially in women.

    DOI: 10.1016/j.pmedr.2024.102782

    Web of Science

    Scopus

    PubMed

  3. Amniotic fluid-derived small extracellular vesicles for predicting postnatal severe outcome of congenital diaphragmatic hernia.

    Matsuo S, Yokoi A, Yoshida K, Kitagawa M, Asano-Inami E, Miura M, Yasui T, Tano S, Ushida T, Imai K, Kajiyama H, Kotani T

    Journal of extracellular biology   3 巻 ( 6 ) 頁: e160   2024年6月

     詳細を見る

    記述言語:英語  

    DOI: 10.1002/jex2.160

    PubMed

  4. Postpartum and interpregnancy care of women with a history of hypertensive disorders of pregnancy

    Ushida, T; Tano, S; Imai, K; Matsuo, S; Kajiyama, H; Kotani, T

    HYPERTENSION RESEARCH   47 巻 ( 6 ) 頁: 1457 - 1469   2024年6月

     詳細を見る

    記述言語:英語   出版者・発行元:Hypertension Research  

    Hypertensive disorders of pregnancy (HDP) are common complications associated with maternal and neonatal morbidity and mortality worldwide. Insights gained from long-term cohort studies have revealed that women with a history of HDP are predisposed to recurrent HDP in subsequent pregnancies and face heightened risks for cardiovascular and metabolic diseases later in life. Pregnancy is a unique condition that overloads maternal cardiac and metabolic functions, and is recognized as a “maternal stress test” for future cardiovascular and metabolic diseases. Pregnancy and postpartum period provide a valuable opportunity for identifying women with underlying and unrecognized cardiovascular and metabolic risk factors. Establishing an effective postpartum healthcare program for women who have experienced HDP is crucial in reducing the future risk of health complications. Postpartum care consists of supportive care for both mothers and children, including not only the assessment of physical and psychological well-being but also long-term postpartum preventive health management. Interpregnancy care is a continuum from postpartum care and includes supportive care to prepare for future pregnancies. Various initiatives across nations have been initiated to establish follow-up programs for women with a history of HDP; however, sufficient evidence of the impact of such programs is not available. Substantial challenges persist in establishing an efficient postpartum follow-up program, including educational strategies, selection of effective lifestyle interventions, and collaboration among various healthcare providers. This review outlines the postpartum and interpregnancy care of women who have experienced HDP as well as the current status and challenges of related healthcare initiatives in Japan. (Figure presented.)

    DOI: 10.1038/s41440-024-01641-7

    Web of Science

    Scopus

    PubMed

  5. Risk factors for non-previa placenta accreta spectrum in pregnancies conceived through frozen embryo transfer during a hormone replacement cycle in Japan

    Matsuo, S; Kotani, T; Tano, S; Ushida, T; Imai, K; Nakamura, T; Osuka, S; Goto, M; Osawa, M; Asada, Y; Kajiyama, H

    REPRODUCTIVE MEDICINE AND BIOLOGY   23 巻 ( 1 ) 頁: e12592   2024年1月

     詳細を見る

    記述言語:英語   出版者・発行元:Reproductive Medicine and Biology  

    Purpose: Non-previa placenta accreta spectrum (PAS) is associated with assisted reproductive technology (ART), particularly frozen embryo transfer during hormone replacement therapy (HRC-FET). We especially aimed to evaluate the prevalence and risk factors for non-previa PAS in HRC-FET pregnancies. Methods: Overall, 279 women who conceived through ART at three ART facilities and delivered at a single center were included in this retrospective study. Data regarding endometrial thickness at embryo transfer, previous histories, and type of embryo transfer—HRC-FET, frozen embryo transfer during a natural ovulatory cycle (NC-FET), and fresh embryo transfer (Fresh-ET)—were collected. Univariable logistic regression analyses were conducted. Results: The prevalence of non-previa PAS was 27/192 (14.1%) in the HRC-FET group and 0 (0.0%) in both the NC-FET and Fresh-ET groups. Significantly high odds ratio [95% confidence interval] of non-previa PAS was associated with a history of artificial abortion (6.45 [1.98–21.02]), endometrial thickness <8.0 mm (6.11 [1.06–35.12]), resolved low-lying placenta (5.73 [2.13–15.41]), multiparity (2.90 [1.26–6.69]), polycystic ovarian syndrome (2.62 [1.02–6.71]), and subchorionic hematoma (2.49 [1.03–6.04]). Conclusions: A history of artificial abortion, endometrial thickness <8.0 mm, and resolved low-lying placenta may help in antenatal detection of a high-risk population of non-previa PAS in HRC-FET pregnancies.

    DOI: 10.1002/rmb2.12592

    Web of Science

    Scopus

    PubMed

科研費 1

  1. ターゲットプロテオミクス応用による母体胎児境界面環境戦略に向けた学際的研究

    研究課題/研究課題番号:23KK0157  2023年9月 - 2027年3月

    科学研究費助成事業  国際共同研究加速基金(海外連携研究)

    小谷 友美, 牛田 貴文, 伊吉 祥平, 松尾 聖子

      詳細を見る

    担当区分:研究分担者 

    わが国では約1/13人が生殖補助医療(ART)で誕生する。ART妊娠に多い合併症に、癒着胎盤スペクトラム及び妊娠高血圧腎症がある。いずれも母児間境界面における絨毛細胞(胎児)と間葉系脱落膜細胞(母体)との相互作用による胎盤絨毛浸潤異常(各々過剰・不全)が関与する。母児間境界面を一つの包括的環境基軸と見なし、「胎児-母体間の細胞コミュニケーション」をつなぐ主要な媒体であるペプチドに着目する。 Schilling博士(フライブルグ大学)との国際共同研究を通して、ターゲットプロテオミクス解析を用いて機序を解明し、ペプチダーゼ阻害剤の創薬につなげ、ART妊娠女性への新たな治療開発を目指す。